[Glioblastoma incident studies from May 2006 to May 2007 in Angers and Nice, France].
The present work is a retrospective study on glioblastomas treated in the Angers and Nice Hospital Departments of Neurosurgery between 2006 and 2007. This study was conducted 2 years after the audit on incident glioblastoma in France in 2004. New events that may modify the care or survival of glioblastoma have occurred since 2004, justifying the present study. The results show that the Karnowsky Index is more often included in the clinical files and that the rate of complete resection has increased, indicating that neurosurgeons are becoming aware of neuro-oncology. Patients with total resection still have the longest survival (14 months). Surprisingly, less than half the patients having surgery received concomitant radiochemotherapy according to the Stupp protocol. Median overall survival remains at 9 months with intention to treat. For patients treated with concomitant chemoradiotherapy with temozolomide, the median survival is 12 months. For patients having a total resection, the median survival is 14 months, whatever adjuvant treatment is used. Median survival for patients having total resection and chemoradiotherapy with temozolomide is 18 months, with a 23.3% 2-year survival rate, less than the ORTC trial rate.
Delion
M
M
Département de neurochirurgie, CHU d'Angers, 4, rue Larrey, 49940 Angers cedex 9, France.
Moraru
C
C
Almayrac
F
F
Von Langsdorff
D
D
Paquis
P
P
Menei
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000628:therapy*; D005260:Female; D005602:France; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D055815:Young Adult